Analyst Julian Harrison of BTIG maintained a Buy rating on Avalo Therapeutics (AVTX – Research Report), retaining the price target of $40.00.
Julian Harrison’s rating is based on Avalo Therapeutics’ promising potential in the treatment of hidradenitis suppurativa (HS) through their AVTX-009 drug. The HS market is projected to grow significantly, and AVTX-009 is expected to stand out due to its superior characteristics, such as greater potency and bioavailability compared to existing treatments like lutikizumab.
Additionally, the company’s financial position is strong, with sufficient cash reserves to fund operations into 2027, allowing them to continue advancing their clinical trials. The broader applicability of AVTX-009 in other autoimmune diseases further enhances its potential market impact, making it a compelling investment opportunity.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $48.00 price target.
AVTX’s price has also changed moderately for the past six months – from $9.720 to $8.220, which is a -15.43% drop .